Neogenomics (NEO) Current Deferred Revenue (2017 - 2026)

Neogenomics has reported Current Deferred Revenue for 10 years, with the latest figure at $899000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 38.51% year-over-year to $899000.0; the trailing twelve-month figure through Mar 2026 stood at $899000.0 (down 38.51% YoY), and the FY2025 full-year result was $1.2 million, up 202.44% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $899000.0, down from $1.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $7.6 million in Q4 2022, with the low at $409000.0 in Q4 2024.
• Historically, Current Deferred Revenue has averaged $3.2 million across 5 years, with a median of $1.6 million in 2025.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 83.72% — and 2025, when it jumped 202.44%.
• Neogenomics' Current Deferred Revenue stood at $7.6 million in 2022, then sank by 71.81% to $2.1 million in 2023, then sank by 80.8% to $409000.0 in 2024, then jumped by 202.44% to $1.2 million in 2025, then slipped by 27.32% to $899000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $899000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.